You are not logged in.

Lovastatin for the adjunctive treatment of schizophrenia: a preliminary randomized double-blind placebo-controlled trial.

Ghanizadeh,A, Rezaee,Z, Dehbozorgi,S, Berk,M and Akhondzadeh,S 2014, Lovastatin for the adjunctive treatment of schizophrenia: a preliminary randomized double-blind placebo-controlled trial., Psychiatry Research, vol. 219, no. 3, pp. 431-435, doi: 10.1016/j.psychres.2014.06.039.

Attached Files
Name Description MIMEType Size Downloads

Title Lovastatin for the adjunctive treatment of schizophrenia: a preliminary randomized double-blind placebo-controlled trial.
Author(s) Ghanizadeh,A
Rezaee,Z
Dehbozorgi,S
Berk,MORCID iD for Berk,M orcid.org/0000-0002-5554-6946
Akhondzadeh,S
Journal name Psychiatry Research
Volume number 219
Issue number 3
Start page 431
End page 435
Publisher Elsevier
Place of publication Amsterdam, The Netherlands
Publication date 2014-11-30
ISSN 1872-7123
Keyword(s) Inflammation
Lovastatin
Oxidative stress
Risperidone
Schizophrenia
Statins
Science & Technology
Life Sciences & Biomedicine
Psychiatry
LIPID-LOWERING MEDICATIONS
MAJOR DEPRESSIVE DISORDER
N-ACETYL CYSTEINE
ADD-ON THERAPY
BIPOLAR DISORDER
STATIN USE
METAANALYSIS
ANTIPSYCHOTICS
ACTIVATION
CELECOXIB
Summary While statins target many of the pathways to neuroprogression in schizophrenia, the safety and efficacy of statins for treating schizophrenia has never been examined. This is an 8-week randomized double blind controlled clinical trial examining the efficacy and safety of adjunctive lovastatin (20 mg/day) treatment or placebo for people with schizophrenia. The baseline characteristics of the two groups were not different. Endpoint changes in Positive and Negative Syndrome Scale (PANSS) total and subscale scores did not differ between the two groups. However there was a significant difference between the doses of risperidone used in the two groups. The mean dose in the lovastatin and placebo groups were 4.8(1.8) and 3.4(1.4) mg/day, respectively (P<.03). No serious adverse events were reported. Slowness of movements, muscle rigidity, increased appetite, and decreased energy were the most common adverse effects, and these rates did not differ between the two groups. This study failed to demonstrate a benefit of lovastatin on symptoms of schizophrenia. This combination was well tolerated. However, a higher dosage of risperidone was used for treating the disorder in those taking concomitant lovastatin compared to placebo.
Language eng
DOI 10.1016/j.psychres.2014.06.039
Field of Research 110999 Neurosciences not elsewhere classified
Socio Economic Objective 920410 Mental Health
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Persistent URL http://hdl.handle.net/10536/DRO/DU:30067177

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 3 times in TR Web of Science
Scopus Citation Count Cited 5 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 388 Abstract Views, 2 File Downloads  -  Detailed Statistics
Created: Thu, 30 Oct 2014, 14:33:52 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.